Literature DB >> 23067355

A characterization and targeting of the infarct border zone in a swine model of myocardial infarction.

Jason M Duran1, Sharven Taghavi, Remus M Berretta, Catherine A Makarewich, Thomas Sharp Iii, Tim Starosta, Foram Udeshi, Jon C George, Hajime Kubo, Steven R Houser.   

Abstract

INTRODUCTION: Novel therapies for myocardial infarction (MI) involving stem cells, gene therapy, biomaterials, or revascularization strategies have shown promise in animal studies and clinical trials, but results have been limited partially due to the injection of therapeutics into ischemic myocardium that cannot support their mechanism of action. Accurate targeting of therapeutics precisely to the infarct border zone (BZ) may be essential for effective repair of the ischemic heart.
METHODS: Ischemia-reperfusion MI was induced in Yorkshire swine by inflation of an angioplasty balloon in the left anterior descending coronary artery. Fluorescent microspheres were injected into the BZ under NOGA catheter guidance, and this location was identified grossly then examined by immunohistochemistry and Western analysis.
RESULTS: Analysis of the infarct zone two hours post-MI revealed a frankly necrotic region devoid of contractile proteins with marked activation of caspase-3. The NOGA-defined BZ closely approximates the grossly-defined BZ and contains intact myocytes and vasculature. Western analysis detected Akt expression and levels of Ca(2+) handling proteins equivalent to that of viable tissues.
CONCLUSIONS: Histological and Western analysis revealed that NOGA mapping precisely identifies grossly and molecularly defined infarct BZ at a location where there are still viable cells and vessels capable of supporting novel therapeutic strategies.
© 2012 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23067355      PMCID: PMC3880852          DOI: 10.1111/j.1752-8062.2012.00432.x

Source DB:  PubMed          Journal:  Clin Transl Sci        ISSN: 1752-8054            Impact factor:   4.689


  29 in total

1.  Intracoronary autologous bone-marrow cell transfer after myocardial infarction: the BOOST randomised controlled clinical trial.

Authors:  Kai C Wollert; Gerd P Meyer; Joachim Lotz; Stefanie Ringes-Lichtenberg; Peter Lippolt; Christiane Breidenbach; Stephanie Fichtner; Thomas Korte; Burkhard Hornig; Diethelm Messinger; Lubomir Arseniev; Bernd Hertenstein; Arnold Ganser; Helmut Drexler
Journal:  Lancet       Date:  2004 Jul 10-16       Impact factor: 79.321

2.  Frequency-encoding Thr17 phospholamban phosphorylation is independent of Ser16 phosphorylation in cardiac myocytes.

Authors:  D Hagemann; M Kuschel; T Kuramochi; W Zhu; H Cheng; R P Xiao
Journal:  J Biol Chem       Date:  2000-07-21       Impact factor: 5.157

3.  Phase 1/2 placebo-controlled, double-blind, dose-escalating trial of myocardial vascular endothelial growth factor 2 gene transfer by catheter delivery in patients with chronic myocardial ischemia.

Authors:  Douglas W Losordo; Peter R Vale; Robert C Hendel; Charles E Milliken; F David Fortuin; Nancie Cummings; Richard A Schatz; Takayuki Asahara; Jeffrey M Isner; Richard E Kuntz
Journal:  Circulation       Date:  2002-04-30       Impact factor: 29.690

Review 4.  Imaging: guiding the clinical translation of cardiac stem cell therapy.

Authors:  Patricia K Nguyen; Feng Lan; Yongming Wang; Joseph C Wu
Journal:  Circ Res       Date:  2011-09-30       Impact factor: 17.367

5.  Patients with end-stage congestive heart failure treated with beta-adrenergic receptor antagonists have improved ventricular myocyte calcium regulatory protein abundance.

Authors:  H Kubo; K B Margulies; V Piacentino; J P Gaughan; S R Houser
Journal:  Circulation       Date:  2001-08-28       Impact factor: 29.690

6.  Cardiac stem cells in patients with ischaemic cardiomyopathy (SCIPIO): initial results of a randomised phase 1 trial.

Authors:  Roberto Bolli; Atul R Chugh; Domenico D'Amario; John H Loughran; Marcus F Stoddard; Sohail Ikram; Garth M Beache; Stephen G Wagner; Annarosa Leri; Toru Hosoda; Fumihiro Sanada; Julius B Elmore; Polina Goichberg; Donato Cappetta; Naresh K Solankhi; Ibrahim Fahsah; D Gregg Rokosh; Mark S Slaughter; Jan Kajstura; Piero Anversa
Journal:  Lancet       Date:  2011-11-14       Impact factor: 79.321

7.  Differentiation of bone marrow stromal cells into the cardiac phenotype requires intercellular communication with myocytes.

Authors:  Meifeng Xu; Maqsood Wani; Yan-Shan Dai; Jiang Wang; Mei Yan; Ahmar Ayub; Muhammad Ashraf
Journal:  Circulation       Date:  2004-10-18       Impact factor: 29.690

Review 8.  Altered beta-adrenergic receptor gene regulation and signaling in chronic heart failure.

Authors:  J D Port; M R Bristow
Journal:  J Mol Cell Cardiol       Date:  2001-05       Impact factor: 5.000

9.  Bone marrow cells regenerate infarcted myocardium.

Authors:  D Orlic; J Kajstura; S Chimenti; I Jakoniuk; S M Anderson; B Li; J Pickel; R McKay; B Nadal-Ginard; D M Bodine; A Leri; P Anversa
Journal:  Nature       Date:  2001-04-05       Impact factor: 49.962

10.  Phospholamban phosphorylation in ischemia-reperfused heart. Effect of pacing during ischemia and response to a beta-adrenergic challenge.

Authors:  Cecilia Mundiña-Weilenmann; Matilde Said; Leticia Vittone; Paola Ferrero; Alicia Mattiazzi
Journal:  Mol Cell Biochem       Date:  2003-10       Impact factor: 3.396

View more
  14 in total

1.  Bone-derived stem cells repair the heart after myocardial infarction through transdifferentiation and paracrine signaling mechanisms.

Authors:  Jason M Duran; Catherine A Makarewich; Thomas E Sharp; Timothy Starosta; Fang Zhu; Nicholas E Hoffman; Yumi Chiba; Muniswamy Madesh; Remus M Berretta; Hajime Kubo; Steven R Houser
Journal:  Circ Res       Date:  2013-06-25       Impact factor: 17.367

2.  Cortical Bone Stem Cell Therapy Preserves Cardiac Structure and Function After Myocardial Infarction.

Authors:  Thomas E Sharp; Giana J Schena; Alexander R Hobby; Timothy Starosta; Remus M Berretta; Markus Wallner; Giulia Borghetti; Polina Gross; Daohai Yu; Jaslyn Johnson; Eric Feldsott; Danielle M Trappanese; Amir Toib; Joseph E Rabinowitz; Jon C George; Hajime Kubo; Sadia Mohsin; Steven R Houser
Journal:  Circ Res       Date:  2017-09-14       Impact factor: 17.367

3.  Rationale and design of the Percutaneous Stem Cell Injection Delivery Effects on Neomyogenesis in Dilated Cardiomyopathy (the POSEIDON-DCM study): a phase I/II, randomized pilot study of the comparative safety and efficacy of transendocardial injection of autologous mesenchymal stem cell vs. allogeneic mesenchymal stem cells in patients with non-ischemic dilated cardiomyopathy.

Authors:  Muzammil Mushtaq; Darcy L DiFede; Samuel Golpanian; Aisha Khan; Samirah A Gomes; Adam Mendizabal; Alan W Heldman; Joshua M Hare
Journal:  J Cardiovasc Transl Res       Date:  2014-10-30       Impact factor: 4.132

4.  Endocardial Gene Delivery Using NOGA Catheter System.

Authors:  Satu Siimes; Niko Järveläinen; Henna Korpela; Seppo Ylä-Herttuala
Journal:  Methods Mol Biol       Date:  2022

5.  Myocardial viability of the peri-infarct region measured by T1 mapping post manganese-enhanced MRI correlates with LV dysfunction.

Authors:  Yuko Tada; Shahriar Heidary; Atsushi Tachibana; Junaid Zaman; Evgenios Neofytou; Rajesh Dash; Joseph C Wu; Phillip C Yang
Journal:  Int J Cardiol       Date:  2019-01-31       Impact factor: 4.164

6.  Modulating mitochondrial dynamics attenuates cardiac ischemia-reperfusion injury in prediabetic rats.

Authors:  Chayodom Maneechote; Siripong Palee; Sasiwan Kerdphoo; Thidarat Jaiwongkam; Siriporn C Chattipakorn; Nipon Chattipakorn
Journal:  Acta Pharmacol Sin       Date:  2021-03-12       Impact factor: 6.150

7.  Cyclin D2 Overexpression Enhances the Efficacy of Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes for Myocardial Repair in a Swine Model of Myocardial Infarction.

Authors:  Meng Zhao; Yuji Nakada; Yuhua Wei; Weihua Bian; Yuxin Chu; Anton V Borovjagin; Min Xie; Wuqiang Zhu; Thanh Nguyen; Yang Zhou; Vahid Serpooshan; Gregory P Walcott; Jianyi Zhang
Journal:  Circulation       Date:  2021-05-06       Impact factor: 39.918

8.  Multimodality infarct identification for optimal image-guided intramyocardial cell injections.

Authors:  F J van Slochteren; R van Es; S Koudstaal; T I G van der Spoel; J P G Sluijter; J Verbree; R H R Pruim; J P W Pluim; T Leiner; P A Doevendans; S A J Chamuleau
Journal:  Neth Heart J       Date:  2014-11       Impact factor: 2.380

9.  Interaction of the Joining Region in Junctophilin-2 With the L-Type Ca2+ Channel Is Pivotal for Cardiac Dyad Assembly and Intracellular Ca2+ Dynamics.

Authors:  Polina Gross; Jaslyn Johnson; Carlos M Romero; Deborah M Eaton; Claire Poulet; Jose Sanchez-Alonso; Carla Lucarelli; Jean Ross; Andrew A Gibb; Joanne F Garbincius; Jonathan Lambert; Erdem Varol; Yijun Yang; Markus Wallner; Eric A Feldsott; Hajime Kubo; Remus M Berretta; Daohai Yu; Victor Rizzo; John Elrod; Abdelkarim Sabri; Julia Gorelik; Xiongwen Chen; Steven R Houser
Journal:  Circ Res       Date:  2020-10-23       Impact factor: 17.367

10.  Development of a closed-artery catheter-based myocardial infarction in pigs using sponge and lidocaine hydrochloride infusion to prevent irreversible ventricular fibrillation.

Authors:  Rafael Dariolli; Celso K Takimura; Carlos A Campos; Pedro A Lemos; José E Krieger
Journal:  Physiol Rep       Date:  2014-08-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.